Virtual Library
Start Your Search
Noorwati Sutandyo
Author of
-
+
P1.01 - Advanced NSCLC (ID 757)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Advanced NSCLC
- Presentations: 2
- Moderators:
- Coordinates: 10/16/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P1.01-026 - Circulating miR-206 in Advanced Stage Lung Cancer Patients and Its Association with Cancer Cachexia (ID 8061)
09:30 - 09:30 | Presenting Author(s): Noorwati Sutandyo
- Abstract
Background:
Cancer cachexia is a common problem found in advanced stage cases. Pathophysiology of cachexia is complicated, involving cytokines and regulator molecules such as microRNA (miRNA). MiR-206, a specific miRNA in skeletal muscle cells was thought to play important role in regulating skeletal muscle loss but have not been studied well in cachectic patients.
Method:
A cross-sectional study was performed in Dharmais Cancer Hospital, Jakarta between September and December 2015. Subjects were patients with advanced lung cancers. Cachexia was defined as body mass index less than 20 kg/m[2] calculated after treatment. MiR-206 expression was assayed using quantitative real-time polymerase chain reaction (RT-PCR), whereas miR-16 served as internal control. Blood from health subjects were also taken for comparison. The results were expressed as cycle threshold (C~T~) and fold change (FC) which was calculated using the 2[-ΔΔC]~T~ method.
Result:
Thirty-seven patients were enrolled; 27 (73.0%) were men. Patients’ mean age was 51.7+11.1 years. Most of the patients (91.9%) were in stage IV. There were 16 (43.2%) patients with cachexia after treatment. Compared to normal healthy subjects, circulating miR-206 expression level was 13.7 times higher in lung cancer patients (FC=13.699). Among cancer patients, miR-206 expression was slightly up-regulated in cachectic than non-cachectic patients (FC=1.355).
Conclusion:
Circulating miR-206 is overexpressed in advanced stage lung cancer patients. Increased circulating miR-206 in cachectic patients may reflect extensive skeletal muscle loss associated with cancer cachexia.
-
+
P1.01-067 - Characteristics and Survival Rate of Non-Small Cell Lung Cancer in Patients 45 Years of Age or Younger (ID 8191)
09:30 - 09:30 | Presenting Author(s): Noorwati Sutandyo
- Abstract
Background:
Lung cancer in younger patients (45 years of age and younger) is rarely found and has different characteristics with older patients. In this study we are looking for characteristics and survival rate of younger NSCLC patients at Indonesia.
Method:
NSCLC patients that came to Dharmais Cancer Center during January 2005 – December 2015 aged 45 years or younger were included in this study. We analyzed patients’ age, gender, history of smoking, histology type, stage, therapy and survival rate.
Result:
Out of 956 NSCLC patients, there were 134 young patients (13.9%). Median age of patient is 39 years old. The most common range of age is 41-45 years old (n=57, 42.5%) with more male patients compared to female patients (n=92, 68.7%). 108 young NSCLC patients (80.6%) did not have history of smoking. Adenocarcinoma is the most common histology type found (59%) and stage IV (52.2%) is most frequent in this study. There is no significant difference between gender and diagnosis (p=0.737), stage (p=0.170), history of smoking and type of histology (p=0.534) in younger NSCLC patients. Median survival rate of the younger patients is 12.2 months (95% CI: 11.045 – 13.355), compared with older patients being 13.2 months (95% CI: 11.547 – 14.853). There is no significant difference between survival rate of younger NSCLC patients and older patients (p=0.543). Patients with EGFR mutation does not have significant association with gender (p=0.07), history of smoking (p=0.259), amount of cigarettes per day (p=0.942), and Brinkman Index (p=0.366). There is a significant difference of survival rate between patients who have EGFR mutation and those who do not (27.4 months VS. 12.2 months; p=0.05). There is no significant difference between patients with EGFR mutation who received target therapy and those who did not (p=0.426). However, there is a significant difference between patients without EGFR mutation who received chemotherapy and those who did not (15.2 months vs. 11.5 months, p=0.05).
Conclusion:
NSCLC in younger patients have shorter survival rate compared with older patients. Survival rate in patients with EGFR mutation who received chemotherapy is better.
